Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 1205 drug-target rows in SSL view, for TSG = SMAD4.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib SMAD4 KIT 7
sunitinib SMAD4 MET 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SMAD4 KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) SMAD4 KIT 4
crizotinib SMAD4 MET 7
gemcitabine SMAD4 RRM1 7
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SMAD4 TYMS 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SMAD4 CMPK1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine SMAD4 RRM1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMAD4 WEE1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMAD4 AKT1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMAD4 MET 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMAD4 BTK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMAD4 KIT 3
capecitabine, cisplatin SMAD4 TYMS 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus SMAD4 MTOR 3
gemcitabine SMAD4 TYMS 3
gemcitabine SMAD4 CMPK1 3
pembrolizumab, belzutifan, lenvatinib SMAD4 KIT 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab SMAD4 TYMS 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab SMAD4 CMPK1 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab SMAD4 RRM1 3
avapritinib SMAD4 KIT 7
cabozantinib SMAD4 MET 7
capecitabine SMAD4 TYMS 7
everolimus SMAD4 MTOR 7
ibrutinib SMAD4 BTK 7
pazopanib SMAD4 KIT 7
regorafenib SMAD4 KIT 7
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin SMAD4 TYMS 2
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin SMAD4 CMPK1 2
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin SMAD4 RRM1 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin SMAD4 TYMS 2
adavosertib, radiation therapy SMAD4 WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMAD4 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SMAD4 MET 2
alvocidib, paclitaxel SMAD4 CDK9 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SMAD4 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SMAD4 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SMAD4 CMPK1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SMAD4 RRM1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 SMAD4 TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMAD4 TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMAD4 BTK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SMAD4 KIT 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis SMAD4 TYMS 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging SMAD4 TYMS 2
biospecimen collection, computed tomography, pemetrexed SMAD4 TYMS 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib SMAD4 MET 2
capecitabine, carboplatin, epirubicin hydrochloride SMAD4 TYMS 2
capecitabine, docetaxel SMAD4 TYMS 2
capecitabine, irinotecan hydrochloride SMAD4 TYMS 2
capecitabine, oxaliplatin SMAD4 TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy SMAD4 TYMS 2
capecitabine, temozolomide SMAD4 TYMS 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy SMAD4 TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery SMAD4 TYMS 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy SMAD4 TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy SMAD4 TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy SMAD4 TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy SMAD4 TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy SMAD4 TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy SMAD4 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab SMAD4 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab SMAD4 CMPK1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab SMAD4 RRM1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study SMAD4 MTOR 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel SMAD4 TYMS 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 SMAD4 TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy SMAD4 TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy SMAD4 TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium SMAD4 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study SMAD4 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SMAD4 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SMAD4 HDAC2 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy SMAD4 TYMS 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SMAD4 KIT 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide SMAD4 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib SMAD4 TYMS 2
irinotecan, capecitabine SMAD4 TYMS 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine SMAD4 DCK 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine SMAD4 RRM1 2
laboratory biomarker analysis, oxaliplatin, pralatrexate SMAD4 TYMS 2
lenvatinib, pembrolizumab SMAD4 KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SMAD4 KIT 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SMAD4 TYMS 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SMAD4 CMPK1 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SMAD4 RRM1 2
m6620, cisplatin, capecitabine, radiotherapy SMAD4 TYMS 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells SMAD4 SLC29A2 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells SMAD4 SLC29A1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed SMAD4 TYMS 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed SMAD4 CMPK1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed SMAD4 RRM1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMAD4 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SMAD4 KIT 2
motexafin gadolinium, radiation therapy SMAD4 RRM2 2
nab-paclitaxel, gemcitabine SMAD4 TYMS 2
nab-paclitaxel, gemcitabine SMAD4 CMPK1 2
nab-paclitaxel, gemcitabine SMAD4 RRM1 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine SMAD4 TYMS 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu SMAD4 TYMS 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu SMAD4 CMPK1 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu SMAD4 RRM1 2
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis SMAD4 TYMS 2
pembrolizumab, guadecitabine, mocetinostat SMAD4 HDAC2 2
pembrolizumab, lenvatinib SMAD4 KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMAD4 TYMS 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SMAD4 KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMAD4 TYMS 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMAD4 CMPK1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMAD4 KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SMAD4 RRM1 2
pemetrexed, bevacizumab SMAD4 TYMS 2
pharmacological study, romidepsin SMAD4 HDAC2 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography SMAD4 TYMS 2
regorafenib, laboratory biomarker analysis SMAD4 KIT 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed SMAD4 TYMS 2
sorafenib, administered orally, ct/mri SMAD4 KIT 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel SMAD4 TYMS 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel SMAD4 CMPK1 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel SMAD4 RRM1 2
temsirolimus SMAD4 MTOR 2
temsirolimus, laboratory biomarker analysis SMAD4 MTOR 2
tislelizumab, pemetrexed SMAD4 TYMS 2
tivantinib SMAD4 MET 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy SMAD4 TYMS 2
pemetrexed SMAD4 TYMS 7
romidepsin SMAD4 HDAC2 7
sorafenib SMAD4 KIT 7
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy SMAD4 TYMS 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging SMAD4 TYMS 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat SMAD4 HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat SMAD4 HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide SMAD4 RRM2 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery SMAD4 TYMS 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis SMAD4 TYMS 1
7-hydroxystaurosporine, fluorouracil SMAD4 TYMS 1
9-ing-41, retifanlimab, gemcitabine, abraxane SMAD4 TYMS 1
9-ing-41, retifanlimab, gemcitabine, abraxane SMAD4 CMPK1 1
9-ing-41, retifanlimab, gemcitabine, abraxane SMAD4 RRM1 1
abbv-400, budigalimab, fluorouracil, leucovorin, oxaliplatin SMAD4 TYMS 1
abemaciclib, ly3023414, gemcitabine, capecitabine SMAD4 TYMS 1
abemaciclib, ly3023414, gemcitabine, capecitabine SMAD4 CMPK1 1
abemaciclib, ly3023414, gemcitabine, capecitabine SMAD4 RRM1 1
abraxane (nab-paclitaxel), gemcitabine SMAD4 TYMS 1
abraxane (nab-paclitaxel), gemcitabine SMAD4 CMPK1 1
abraxane (nab-paclitaxel), gemcitabine SMAD4 RRM1 1
adavosertib SMAD4 WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy SMAD4 WEE1 1
adavosertib, radiation therapy, temozolomide SMAD4 WEE1 1
adct-601, gemcitabine SMAD4 TYMS 1
adct-601, gemcitabine SMAD4 CMPK1 1
adct-601, gemcitabine SMAD4 RRM1 1
adebrelimab, apatinib, tegafur SMAD4 TYMS 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy SMAD4 HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid SMAD4 HDAC2 1
aee788, everolimus SMAD4 MTOR 1
afatinib dimaleate, capecitabine, laboratory biomarker analysis SMAD4 TYMS 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMAD4 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMAD4 BTK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SMAD4 KIT 1
ag-013736, gemcitabine, gemcitabine, placebo SMAD4 TYMS 1
ag-013736, gemcitabine, gemcitabine, placebo SMAD4 CMPK1 1
ag-013736, gemcitabine, gemcitabine, placebo SMAD4 RRM1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel SMAD4 TYMS 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel SMAD4 CMPK1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel SMAD4 RRM1 1
ags-1c4d4, gemcitabine SMAD4 TYMS 1
ags-1c4d4, gemcitabine SMAD4 CMPK1 1
ags-1c4d4, gemcitabine SMAD4 RRM1 1
ak104, ak104, gemcitabine, nab-paclitaxel SMAD4 TYMS 1
ak104, ak104, gemcitabine, nab-paclitaxel SMAD4 CMPK1 1
ak104, ak104, gemcitabine, nab-paclitaxel SMAD4 RRM1 1
ak104, oxaliplatin, capecitabine SMAD4 TYMS 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine SMAD4 TYMS 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine SMAD4 CMPK1 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine SMAD4 RRM1 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib SMAD4 TYMS 1
albumin-bound paclitaxel (abi-007), gemcitabine SMAD4 TYMS 1
albumin-bound paclitaxel (abi-007), gemcitabine SMAD4 CMPK1 1
albumin-bound paclitaxel (abi-007), gemcitabine SMAD4 RRM1 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim SMAD4 TYMS 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes SMAD4 DCK 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes SMAD4 RRM1 1
alisertib, gemcitabine SMAD4 TYMS 1
alisertib, gemcitabine SMAD4 CMPK1 1
alisertib, gemcitabine SMAD4 RRM1 1
alpelisib, everolimus, exemestane SMAD4 MTOR 1
alvocidib, docetaxel SMAD4 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis SMAD4 CDK9 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox SMAD4 TYMS 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox SMAD4 CMPK1 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox SMAD4 RRM1 1
amg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, capecitabine, cisplatin, capecitabine, cisplatin, capecitabine SMAD4 TYMS 1
amg 479, placebo, amg 479, gemcitabine SMAD4 TYMS 1
amg 479, placebo, amg 479, gemcitabine SMAD4 CMPK1 1
amg 479, placebo, amg 479, gemcitabine SMAD4 RRM1 1
amivantamab SMAD4 MET 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel SMAD4 TYMS 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.